Semaglutide oral - Novo Nordisk

Drug Profile

Semaglutide oral - Novo Nordisk

Alternative Names: GLP-1-SNAC; NN-9924; NNC0113-0217; OG-217SC

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2017 Phase-III clinical trials in Type-2 diabetes mellitus in Canada (PO) (NCT03021187)
  • 01 Feb 2017 Novo Nordisk initiates enrolment in the PIONEER 8 trial for Type-2 diabetes mellitus in USA, France, Greece, Japan, Mexico, Poland and Russia (NCT03021187)
  • 12 Jan 2017 Novo Nordisk plans the phase III PIONEER 8 - Insulin add-on trial for Type-2 diabetes mellitus in Canada, France, Greece, India, Japan, Mexico, Poland, Russia and USA (PO) (NCT03021187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top